MNKD
MANNKIND CORP
NASDAQ · Healthcare · Biotechnology · US
$3.09
+1.64%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.16
From 52W high−50.24%
Volume2.46M
Market cap$993.57M
P/E (TTM)—
P/S (TTM)2.5x
Div yield—
Key dataOct 19, 2026
Open
$3.16
From 52W high
−50.24%
Volume
2.46M
Market cap
$993.57M
ValuationView details →
P/E (Fwd)
107.5x
EV/EBITDA
40.3x
P/E (TTM)
—
RSI (14)
38.6
MomentumView details →
1D Return
+1.64%
YTD Return
−44.89%
SummaryUpdated Jun 1, 2026
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company founded in 1991 and headquartered in Westlake Village, California. The company has transformed from a single-product diabetes-focused entity into a diversified biopharmaceutical company with multiple revenue streams. MannKind specializes in developing and commercializing inhaled therapeutic products using its proprietary <b>Technosphere</b> drug delivery platform, primarily targeting endocrine disorders and orphan lung diseases. The company went public in 2004 and has evolved significantly over the past two decades, particularly accelerating its diversification strategy since 2022.
Similar companies
Latest newsMore news →
MannKind and Rose Pharma Inc entered a licensing and collaboration agreement to develop an inhaled rapid-acting, short-duration GLP-1 for weight management, combining Rose Pharma's investigational GLP-1 receptor agonist with MannKind's Technosphere inhalation technology.41d agoMannKind Corp reported Q2 2026 total revenue of $109.4 million, up 43% year-over-year, with a net loss of $19.1 million, driven by strong sales of Afrezza and Furoscix.76d ago